Epidemiologist Dr Alanna Chamberlain (Mayo Clinic, MN, USA) and colleagues assessed the changes in BP control between pre-pandemic and pandemic periods [1]. Included in the analysis were 24 US health systems (18 academic). The extracted data was standardised to the PCORnet common data model. The study compared 3 qualitative measures of BP control and improvement, and 6 process metrics relevant to clinical management and treatment practice for BP control between 2019 (pre-pandemic year) and 2020 (pandemic year).
In 2019, 1.77 million patients with hypertension had a combined 8.30 million healthcare encounters. In 2020, a similar number of patients (1.73 million) was followed but fewer encounters (6.59 million) were reported. The percentage of hypertensive patients who demonstrated BP control (<140/<90 mmHg) at an ambulatory care visitation had dropped from 60.5% in 2019 to 53.3% in 2020, displaying a difference in weighted averages of 7.2%. A similar trend was observed in the <130/<80 mmHg category, featuring a 4.6% reduction in BP control.
Achieved improvements in BP control, defined as a systolic BP reduction of 10 mmHg or a systolic BP<140 mmHg, declined from 29.7% in 2019 to 23.8% in 2020. The number of repeat visits among patients with uncontrolled hypertension dropped from 36.7% in the pre-pandemic year to 31.7% in the pandemic year. The proportion of patients who was prescribed an intensification of medication remained stable. Dr Chamberlain mentioned that they observed a large variance in BP control metrics across health systems, suggesting an opportunity for improvement.
- Chamberlain AM, et al. Disruption in Blood Pressure Control with the COVID-19 Pandemic: A Study of 24 US Health Systems in the PCORnet Blood Pressure Control Laboratory. LBS02, AHA Scientific Sessions 2021, 13–15 November.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19 Next Article
Concomitant tricuspid annuloplasty reduces treatment failure in moderate tricuspid regurgitation »
« Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19 Next Article
Concomitant tricuspid annuloplasty reduces treatment failure in moderate tricuspid regurgitation »
Table of Contents: AHA 2021
Featured articles
The scope of remote healthcare in hypertension and hyperlipidaemia
Atrial Fibrillation
New developments in remote diagnostics and monitoring of AF
Head-to-head: Efficacy of dabigatran versus warfarin on cognitive impairment
Posterior left pericardiotomy safe and effective in reducing atrial fibrillation
LAA ligation did not reduce recurrent atrial arrhythmias in persistent AF
Equal benefits of early rhythm control in AF subtypes
CVD Risk Reduction
Remote healthcare programme improves hypertension and lipid control
Novel oral PCSK9 inhibitor shows promising results for hypercholesterolaemia
REVERSE-IT: Interim analysis shows promising effect of bentracimab on ticagrelor reversal
No significant effect of aspirin on reducing cognitive impairment
Milvexian phase 2 data supports safety and efficacy for VTE prevention after total knee replacement
Network meta-analysis observes no clear effect of eicosapentaenoic acid on CV outcomes
Heart Failure
Empagliflozin efficacious in HF patients with preserved ejection fractions ≥50%
EMPULSE: Empagliflozin improves outcomes of acute heart failure
CHIEF-HF: Canagliflozin improves health status in heart failure
DREAM-HF: MPC therapy for HFrEF did not meet primary endpoint
Therapeutic approaches in heart failure with diabetes
Acute Coronary Syndrome
Ticagrelor cessation: early CABG non-inferior to delayed surgery
Distinguishing patients before AMI based on plaque morphology
Vascular Diseases: PVD
Rivaroxaban regimen beneficial after revascularisation for claudication
LIBERTY 360 shows quality-of-life improvements after peripheral vascular intervention
Deficient treatment outcomes after PVI in Black and low-income adults with PAD
REDUCE-IT: Cardiovascular risk reduction with icosapent ethyl in PAD
Vascular Diseases: CAD
Long-term reduced risk of CV events with ticagrelor plus aspirin after CABG
Early surgery outperforms conservative management in asymptomatic severe aortic stenosis
External support device for SVG grafts in CABG surgery shows promise
COVID-19 & the Heart
Blood pressure control disrupted during the pandemic
Icosapent ethyl did not reduce the risk of hospitalisation in COVID-19
Neutral effect of P2Y12 inhibitors in non-critical COVID-19 hospitalisations
COVID-19 mRNA vaccination benefits outweigh the risk for myocarditis
Other
2021 Guideline for Chest Pain: Top 10 takeaways
Accurate ejection fraction assessment in paediatric patients via artificial intelligence
Concomitant tricuspid annuloplasty reduces treatment failure in moderate tricuspid regurgitation
Related Articles
January 14, 2022
Remote healthcare programme improves hypertension and lipid control
January 14, 2022
Therapeutic approaches in heart failure with diabetes
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com